ADC Therapeutics (ADCT) Set to Announce Quarterly Earnings on Thursday

ADC Therapeutics (NYSE:ADCT) is scheduled to announce its earnings results before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

ADC Therapeutics (NYSE:ADCT) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. The company had revenue of $17.41 million for the quarter, compared to analyst estimates of $19.06 million. During the same period in the previous year, the business posted ($0.58) earnings per share. On average, analysts expect ADC Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ADC Therapeutics Stock Performance

NYSE:ADCT traded up $0.05 during midday trading on Tuesday, reaching $3.07. The stock had a trading volume of 171,692 shares, compared to its average volume of 632,504. The firm has a fifty day simple moving average of $3.01 and a two-hundred day simple moving average of $3.35. ADC Therapeutics has a 12-month low of $0.36 and a 12-month high of $6.04.

Analysts Set New Price Targets

ADCT has been the topic of several analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $8.00 target price on shares of ADC Therapeutics in a report on Wednesday, August 7th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of ADC Therapeutics in a report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, ADC Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $9.00.

ADC Therapeutics Company Profile

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.